908 Devices Inc. $MASS Stock Position Raised by Sei Investments Co.

Sei Investments Co. grew its position in shares of 908 Devices Inc. (NASDAQ:MASS) by 101.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 164,894 shares of the company’s stock after buying an additional 82,934 shares during the quarter. Sei Investments Co. owned approximately 0.44% of 908 Devices worth $1,009,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in 908 Devices during the second quarter valued at approximately $48,000. Daiwa Securities Group Inc. bought a new stake in 908 Devices in the second quarter worth approximately $61,000. PCM Encore LLC bought a new stake in 908 Devices in the fourth quarter worth approximately $62,000. The Manufacturers Life Insurance Company acquired a new position in shares of 908 Devices during the 2nd quarter worth $77,000. Finally, Walleye Capital LLC acquired a new position in shares of 908 Devices during the 2nd quarter worth $82,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Key 908 Devices News

Here are the key news stories impacting 908 Devices this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. 908 Devices reported a loss of $0.11 per share, better than the $0.14 consensus loss, while revenue reached $16.07 million versus estimates of $15.37 million. Revenue increased 23% year over year, and the company said its adjusted EBITDA loss narrowed by more than half from the prior year. 908 Devices Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Management raised the low end of its full-year outlook. 908 Devices now expects 2026 revenue of $68 million to $70 million, compared with the previous outlook’s lower starting point and roughly in line with the $68.6 million analyst consensus. The company’s guidance excludes potential AVCAD contribution from its core outlook, which may leave room for upside if that business contributes. 908 Devices Signals 2026 Revenue Outlook
• Positive Sentiment: Growth drivers remain intact. Demand for chemical-detection instruments from law enforcement, defense, and other mission-critical customers, along with recurring NIRLab revenue and upgrades such as VipIR, is supporting the bullish view. One analyst publication maintained a BUY rating after the earnings beat. 908 Devices Mission Critical Devices Drive Growth
• Neutral Sentiment: 908 Devices plans to present at the 17th Annual Midwest IDEAS Investor Conference, providing an opportunity for management to discuss its outlook and growth strategy. 908 Devices to Present at the Midwest IDEAS Investor Conference
• Negative Sentiment: Director Christopher D. Brown sold a combined 17,800 shares for approximately $162,000 across August 10 and 11. The sales were conducted under a pre-arranged Rule 10b5-1 plan, reducing their negative signaling value, and Brown still owns 805,559 shares after the transactions. 908 Devices SEC Insider Trading Filing

908 Devices Stock Performance

Shares of NASDAQ:MASS opened at $10.02 on Thursday. The company has a market cap of $378.86 million, a P/E ratio of -10.55 and a beta of 0.66. The stock’s 50-day moving average is $8.26 and its 200-day moving average is $7.36. 908 Devices Inc. has a 52-week low of $5.03 and a 52-week high of $10.52.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. 908 Devices had a negative return on equity of 12.29% and a negative net margin of 56.96%.The business had revenue of $16.07 million during the quarter, compared to analysts’ expectations of $15.37 million. As a group, equities analysts predict that 908 Devices Inc. will post -0.4 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MASS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a research note on Friday, August 7th. Wall Street Zen downgraded shares of 908 Devices from a “buy” rating to a “hold” rating in a research report on Saturday, July 18th. Roth Capital raised their target price on 908 Devices from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Stifel Nicolaus boosted their price target on 908 Devices from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $12.50.

Insider Activity at 908 Devices

In related news, Director Christopher D. Brown sold 30,000 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $9.00, for a total transaction of $270,000.00. Following the transaction, the director owned 895,559 shares of the company’s stock, valued at approximately $8,060,031. The trade was a 3.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Joseph H. Iv Griffith sold 6,940 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $9.03, for a total transaction of $62,668.20. Following the completion of the sale, the chief financial officer directly owned 132,956 shares of the company’s stock, valued at approximately $1,200,592.68. This trade represents a 4.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 106,940 shares of company stock worth $949,714. Company insiders own 28.20% of the company’s stock.

908 Devices Profile

908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company’s core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.

Key products in 908 Devices’ portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.